Biomarin Pharmaceutical (BMRN) Intangibles (2009 - 2026)

Biomarin Pharmaceutical has disclosed Intangibles across 18 years of filings, most recently posting $204.7 million for Q1 2026.

• Quarterly Intangibles fell 17.26% year-over-year to $204.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.7 million (down 17.26% YoY) and the FY2025 annual result came in at $213.8 million, down 16.23% from the prior year.
• Intangibles fell to $204.7 million in Q1 2026, from $213.8 million in the prior quarter.
• Over five years, Intangibles peaked at $374.3 million in Q1 2022 and troughed at $204.7 million in Q1 2026.
• A 5-year average of $286.5 million and a median of $279.7 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles decreased 6.32% — and 2026, when it dropped 17.26%.
• Tracing BMRN's Intangibles over 5 years: stood at $338.6 million in 2022, then declined by 12.96% to $294.7 million in 2023, then declined by 13.38% to $255.3 million in 2024, then fell by 16.23% to $213.8 million in 2025, then dropped by 4.29% to $204.7 million in 2026.
• Business Quant data shows BMRN's Intangibles at $204.7 million in Q1 2026, $213.8 million in Q4 2025, and $233.1 million in Q3 2025.